Literature DB >> 31760487

Early mobilization versus plaster immobilization of simple elbow dislocations: a cost analysis of the FuncSiE multicenter randomized clinical trial.

Esther M M Van Lieshout1, Gijs I T Iordens1, Suzanne Polinder2, Denise Eygendaal3, Michael H J Verhofstad1, Niels W L Schep4, Dennis Den Hartog5.   

Abstract

INTRODUCTION: The primary aim was to assess and compare the total costs (direct health care costs and indirect costs due to loss of production) after early mobilization versus plaster immobilization in patients with a simple elbow dislocation. It was hypothesized that early mobilization would not lead to higher direct and indirect costs.
MATERIALS AND METHODS: This study used data of a multicenter randomized clinical trial (FuncSiE trial). From August 25, 2009 until September 18, 2012, 100 adult patients with a simple elbow dislocation were recruited and randomized to early mobilization (immediate motion exercises; n = 48) or 3 weeks plaster immobilization (n = 52). Patients completed questionnaires on health-related quality of life [EuroQoL-5D (EQ-5D) and Short Form-36 (SF-36 PCS and SF-36 MCS)], health care use, and work absence. Follow-up was 1 year. Primary outcome were the total costs at 1 year. Analysis was by intention to treat.
RESULTS: There were no significant differences in EQ-5D, SF-36 PCS, and SF-36 MCS between the two groups. Mean total costs per patient were €3624 in the early mobilization group versus €7072 in the plaster group (p = 0.094). Shorter work absenteeism in the early mobilization group (10 versus 18 days; p = 0.027) did not lead to significantly lower costs for loss of productivity (€1719 in the early mobilization group versus €4589; p = 0.120).
CONCLUSION: From a clinical and a socio-economic point of view, early mobilization should be the treatment of choice for a simple elbow dislocation. Plaster immobilization has inferior results at almost double the cost.

Entities:  

Keywords:  Cost utility; Cost-effectiveness; Elbow dislocation; Function; Quality of life

Mesh:

Year:  2019        PMID: 31760487      PMCID: PMC7295826          DOI: 10.1007/s00402-019-03309-1

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


Introduction

The elbow is the second most commonly dislocated joint in adults and mostly occurs in young and active persons, thus affecting the working population [1-3]. A simple elbow dislocation (no associated fractures) is a disabling injury which causes considerable pain and loss of range of motion in the short term, which impedes the ability to perform daily activities such as work [4]. Previous studies suggested that early mobilization may give superior functional results [5-11]. The FuncSiE trial compared clinical outcome of early mobilization and plaster immobilization in patients with a simple elbow dislocation. The results of this study showed that early mobilization resulted in earlier recovery of elbow function and work resumption [12]. These results justify the design of a treatment guideline advocating early mobilization from a clinical point of view. However, there are no high-quality studies that report the burden of simple elbow dislocations on direct and indirect health care costs, let alone to what extent early mobilization would be able to reduce these costs. We performed a cost analysis of the FuncSiE randomized controlled trial to assess the direct and indirect costs and the cost-effectiveness of early mobilization versus plaster immobilization in patients with a simple elbow dislocation. It was hypothesized that early mobilization would not lead to higher costs.

Materials and methods

Settings and participants

This cost analysis used data of a multicenter randomized clinical trial comparing early mobilization with plaster immobilization in patients after a simple elbow dislocation (FuncSiE trial). The trial is registered at the Netherlands Trial Register (NTR2025). The results of this study and the study protocol can be read elsewhere [12, 13]. The study was approved by the Medical Research Ethics Committee. All patients gave written informed consent. Adult patients (aged 18 years or older) with a simple elbow dislocation were recruited from August 25, 2009 until September 18, 2012. Polytraumatized patients, patients with recurrent or open dislocation, additional traumatic injuries of the affected arm, an indication for surgical intervention, impaired elbow function pre-trauma, previous surgery or fractures involving the elbow, or expected problems with maintaining follow-up were excluded.

Randomization and masking

Patients were randomly assigned to receive early mobilization (early active movements within the limits of pain, started immediately after closed reduction as tolerated) or plaster immobilization (immobilization in a long arm cast for 3 weeks followed by movements within the limits of pain). In both groups, mobilization was supervised by a physical therapist following a guideline that was designed for this study. Further details concerning the randomization procedure and both interventions can be read in the original article and the study protocol [12, 13].

Assessments and follow-up

Data were obtained during out-patient visits at 1, 3 and 6 weeks, and at 3, 6, and 12 months after randomization. During these visits, patients completed questionnaires concerning health-related quality of life and a health care consumption questionnaire. This questionnaire included questions on the number of visits to the physical therapist, general practitioner, and medical specialist, admission to hospital, rehabilitation center or nursing home, medication use, and the use of home care. The questionnaire also included questions concerning work absenteeism and resumption. Questionnaire data were supplemented with data from the patients’ medical files. The primary outcome measure for this analysis was total costs, consisting of direct costs (i.e., costs for treatment and intramural care) and indirect costs (i.e., costs for lost production). Secondary outcome measures included the health-related quality of life using the EuroQol-5D (EQ-5D) [14] and Short Form-36 (SF-36), which are both validated [15]. The use of the EQ-5D is recommended for assessing quality of life in trauma patients especially for economic assessments [16, 17]. The scores for the physical and mental components of the SF-36 were converted to a norm-based score and compared with the norms for the general population of the United States [15]. As there were no significant differences in quality of life scores between the two groups at 1 year, no cost-effectiveness and cost–utility ratio could be calculated. Therefore, a cost-minimization analysis was performed.

Cost measurement

The total direct and indirect costs of both treatments were analyzed from a societal perspective and included: (1) in-hospital care costs which were subdivided into costs for the primary intervention, costs during follow-up, and costs for diagnosis and treatment of adverse events; (2) out of hospital care costs for rehabilitation; and (3) indirect costs due to productivity loss. Costs were calculated by multiplying the volumes with the corresponding unit prices (Table 1). Hospital costs for the primary intervention and costs during follow-up consisted of fixed and variable costs. As no patients were admitted to a nursing home or rehabilitation clinic, these costs were zero for all patients. Lost productivity was represented by the hours of work absence.
Table 1

Data sources, sources of valuation and unit prices of all cost categories

Cost categoriesUnitNumber of fixed units for EM/PISource of dataSource of valuationUnit price (€)
Hospital costs—primary intervention
Emergency department visitVisit1/1Hospital registryCost manual€161.12
Radiology/diagnostics
 X-rayaX-ray3/3Hospital registryNZa€51.07
 CT scanCT scanVariableHospital registryNZa€202.14
 MRIMRIVariableHospital registryNZa€256.79
 UltrasoundUltrasoundVariableHospital registryNZa€76.64
 ArthrogramArthrogramVariableHospital registryNZa€126.86
Anesthetics/sedationCaseVariableStudy/hospital registryCVZ€2.00b
Plexus block/regional anesthesiaCaseVariableStudy/hospital registryHospital data€82.00
Reduction in operating room
 SurgeonMinuteVariableStudy/hospital registryCost manual€2.41c/€1.83d
 AnesthesiologistMinuteVariableHospital registryCost manual€2.41c/€1.83d
 Operating roomeMinuteVariableStudy/hospital registryHospital data€14.75c/€11.87d
Treatment
 PlasterPlaster0/1Study registryHospital data€127.18
 Plaster change at 1 weekPlaster0/1Study/hospital registryHospital data€158.60
 Pressure bandagePressure bandage1/0Study registryHospital data and https://www.medischservice.nl€15.21
 SlingSling1/1Study registryHospital data and https://www.medischservice.nl€15.00
Admission daysDaysVariableStudy/hospital registryCost manual€464.15c/€613.53d
Visit out-patient clinic or plaster roomfVisit2/2Study/hospital registryCost manual€68.29c/€137.64d
Hospital costs—follow-up
Visit out-patient clinicgVisit4/4Study/hospital registryCost manualAs displayed above
Radiology/diagnosticshStudy1/1Study/hospital registryNZaAs displayed above
Hospital costs—adverse events/revision surgery
Visit out-patient clinic or plaster roomiVisitVariableStudy/hospital registryCost manualAs displayed above
Radiology/diagnosticsjStudyVariableStudy/hospital registryNZaAs displayed above
Operating roomeMinutesVariableHospital registryHospital dataAs displayed above
SurgeonMinutesVariableHospital registryCost manualAs displayed above
AnesthesiologistMinutesVariableHospital registryCost manualAs displayed above
Type of surgery
 ArthrolysiseProcedureVariableHospital dataHospital data€47.10
 Ulnar nerve releaseeProcedureVariableHospital dataHospital data€56.91
 Arthroscopy wristeProcedureVariableHospital dataHospital data€220.17
Admission daysDaysVariableStudy/hospital registryCost manualAs displayed above
Out of hospital costs—follow-up/rehabilitation
General practitionerVisitsVariableStudy registryCost manual€29.88
Physical therapyVisitsVariableStudy registryCost manual€38.41
Home careHoursVariableStudy registryCost manual€37.35
Indirect cost
Work absenteeism males < 35 yearsHoursVariableStudy registryCost manual€25.00
Work absenteeism males ≥ 35 yearsHoursVariableStudy registryCost manual€39.00
Work absenteeism females < 35 yearsHoursVariableStudy registryCost manual€24.00
Work absenteeism females ≥ 35 yearsHoursVariableStudy registryCost manual€30.00

Number of units for fixed costs are displayed for early mobilization (EM) and plaster immobilization (PI)

aProtocolled radiographs prior to and after reduction and after 1 week

bDue to the low costs of medication an estimated average of €2 was maintained per case of anesthetics/sedation

cGeneral hospital

dAcademic hospital

eProtocol cost, only materials (OR use, anesthesiologist and surgeon wages not included) average time for plexus block 15 min. Average operating time for arthrolysis, ulnar nerve release and arthroscopy of the wrist were 240, 190 and 75 min, respectively

fProtocolled visits at 1 and 3 weeks

gProtocolled visits at 6 weeks, 3 months, 6 months and 1 year

hProtocolled radiographs at 1 year

iVisits as a result of adverse events

jDiagnostics as a result of adverse events

Data sources, sources of valuation and unit prices of all cost categories Number of units for fixed costs are displayed for early mobilization (EM) and plaster immobilization (PI) aProtocolled radiographs prior to and after reduction and after 1 week bDue to the low costs of medication an estimated average of €2 was maintained per case of anesthetics/sedation cGeneral hospital dAcademic hospital eProtocol cost, only materials (OR use, anesthesiologist and surgeon wages not included) average time for plexus block 15 min. Average operating time for arthrolysis, ulnar nerve release and arthroscopy of the wrist were 240, 190 and 75 min, respectively fProtocolled visits at 1 and 3 weeks gProtocolled visits at 6 weeks, 3 months, 6 months and 1 year hProtocolled radiographs at 1 year iVisits as a result of adverse events jDiagnostics as a result of adverse events The costs for use of the operating room included cost for personnel, anesthesia (not including the wage of the anesthesiologist), and overhead costs. An estimation of these costs was made by calculating the means of the fixed cost prices, which were derived from four participating hospitals (one academic and three regional hospitals). Cost prices for other health care resources were derived from the Dutch manual on cost research [18]. Unit costs for all diagnostic procedures were derived from the Dutch Health Care Authority (NZa, Nederlandse Zorgautoriteit). Medication costs were calculated using standard unit prices as described by the CVZ (College voor zorgverzekeringen, Health Care Insurance Board; online available at https://www.medicijnkosten.nl). Indirect costs due to productivity loss were calculated using the friction cost method, which assumes that initial production levels restore after some period of adaption, taking economic circumstances into account [19].

Statistical analysis

Analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 21 (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Armonk, NY, USA). The FuncSiE trial was designed to enroll 100 patients. The sample size calculation was performed from a clinical perspective, and is published elsewhere [12, 13]. Analysis was by intention to treat and all statistical tests were two-sided. Missing data were not imputed. Chi-squared analysis was used for statistical testing of categorical data. Univariate analysis of continuous data was done using a Mann–Whitney U test (non-parametric data) or a Student’s T test (parametric data). p values < 0.05 were regarded as statistically significant. Accelerated bootstrapping was used for pairwise comparison of the mean differences in all hospital costs, out of hospital costs, indirect costs and total costs between the two treatment groups. The number of replications was chosen to be 1000. SF-36 and EQ-5D were repeatedly measured over time, and were compared between treatment groups using linear mixed-effects regression models. These multilevel models included random effects for the intercepts of the regression model and time coefficient of individual patients. Since the outcome measures were not linearly related with time, the time points were entered as factor. The models included fixed effects for treatment group, involvement of the dominant side, and gender. The effect of age was non-significant in all models and age was therefore not included. The interaction between treatment group and time was included in the model to test for differences between the groups over time (i.e., differences in recovery time). For each follow-up moment, the estimated marginal mean of the EQ-5D utility score and the SF-36 physical component summery (PCS) and mental component summery (MCS) scores were computed per treatment group and compared post hoc using a Bonferroni test to correct for multiple testing. Absence of overlap in the 95% confidence interval around the marginal means was regarded as significant at p < 0.05.

Results

Of the hundred patients enrolled, 48 were assigned to early mobilization and 52 to plaster immobilization (Fig. 1). All patients received the allocated treatment. At 1 year follow-up, complete cost data were available for 99 patients; one patient in the plaster group was lost to follow-up after 6 months. Apart from a relative predominance of patients with an affected dominant side in the early mobilization group, randomization resulted in similar baseline and injury characteristics in the two groups (Table 2).
Fig. 1

Trial flow chart

Table 2

Characteristics of trial participants by treatment group

Early mobilizationN = 48Plaster immobilizationN = 52
Patient characteristics
 Malea22 (46%)20 (39%)
 Ageb (year)43 (16)47 (14)
 Independent livinga44 (92%)50 (96%)
 Household compositiona
  Alone10 (21%)10 (19%)
  Alone with children1 (2%)3 (6%)
  With partner18 (38%)19 (37%)
  With partner and children13 (27%)17 (33%
  With family/friends6 (13%)3 (6%)
Activities of daily living
 Work participation (N patients)a32 (67%)32 (62%)
 Work participation (h/week)c36.0 (24.0–40.0)36.0 (24.0–40.0)
Injury characteristics
 Dominant side affecteda24 (50%)22 (42%)
 Reduction in operating rooma5 (10%)1 (2%)
 Reduction anesthesiaa
  IV valium21 (44%)17 (33%)
  General anesthesia10 (21%)8 (15%)
  Intra-articular3 (6%)12 (23%)
  None6 (13%)9 (17%)
  Other6 (13%)6 (12%)
  Regional/plexus2 (4%)0 (0%)

Data are presented as aN (%), bmean (SD), or cmedian (P25–P75)

Trial flow chart Characteristics of trial participants by treatment group Data are presented as aN (%), bmean (SD), or cmedian (P25–P75)

Quality of life

No statistically significant differences in health-related quality of life measured with the EQ-5D and SF-36 between the two groups were noted throughout the 1-year follow-up (Table 3). The EQ-5D was consistently between 0.82 and 0.89 during follow-up. The SF-36 PCS varied between 42 and 53 and the SF-36 MCS varied between 55 and 59 throughout the whole follow-up. Both component summary scores remained within the population norm of 50 ± 10 (SD) points, and were independent of treatment.
Table 3

Health-related quality of life at all follow-up moments by treatment group

Outcome scoreFollow-upEarly mobilizationN = 48Plaster immobilizationN = 52
EQ-5D utility score6 weeks0.86 (0.83–0.89)0.82 (0.79–0.85)
3 months0.87 (0.84–0.90)0.86 (0.84–0.89)
6 months0.88 (0.86–0.91)0.88 (0.85–0.91)
12 months0.88 (0.85–0.91)0.89 (0.87–0.92)
SF-36 PCS6 weeks45 (43–48)42 (40–44)
3 months52 (50–54)50 (48–52)
6 months53 (50–55)52 (50–54)
12 months53 (51–55)53 (51–55)
SF-36 MCS6 weeks56 (54–58)59 (57–61)
3 months57 (55–59)57 (55–59)
6 months57 (55–59)56 (54–58)
12 months55 (53–57)56 (54–58)

Data are shown as the estimated marginal mean with 95% confidence interval adjusted for involvement of the dominant side and gender. None of the intervals overlapped indicating no statistical significant difference between the treatment groups

EQ-5D, EuroQoL 5D; SF-36, Short Form-36; PCS, Physical Component Summary score; MCS, Mental Component Summary score

Health-related quality of life at all follow-up moments by treatment group Data are shown as the estimated marginal mean with 95% confidence interval adjusted for involvement of the dominant side and gender. None of the intervals overlapped indicating no statistical significant difference between the treatment groups EQ-5D, EuroQoL 5D; SF-36, Short Form-36; PCS, Physical Component Summary score; MCS, Mental Component Summary score

Health care costs

Total costs and costs per category are shown in Table 4 and Fig. 2. The mean total costs per patient were €3624 (95% confidence interval (CI) 1966–5281) in the early mobilization group versus €7072 (95% CI 3444–10,701) in the plaster group. Although early mobilization was €3449 less expensive than plaster immobilization, this difference was not statistically significant (p = 0.094).
Table 4

Total costs and costs per cost category by treatment group

Cost categoriesEarly mobilizationN = 48Plaster immobilizationN = 52Differencep value
Direct costs€1904 (1303 to 2505)€2483 (1822 to 3144)− €5790.198
Intramural costs€1098 (785 to 1411)€1517 (1004 to 2031)− €4190.173
 Primary intervention€551 (510 to 591)€856 (551 to 1161)− €3050.058
 Follow-up€382 (349 to 415)€399 (364 to 434)− €170.481
 Adverse events/revision surgery€166 (− 147 to 478)€263 (− 153 to 678)− €970.712
Out of hospital costs (FU/rehabilitation)€806 (465 to 1147)€966 (660 to 1271)− €1600.483
Indirect costs (productivity loss)€1719 (465 to 2974)€4589 (1258 to 7920)− €28700.120
Total€3624 (1966 to 5281)€7072 (3444 to 10,701)− €34490.094

Data are shown as the mean costs per patient with 95% confidence interval given between brackets and were analyzed with a regression analysis after bootstrapping

FU, follow-up

Fig. 2

Mean total costs and costs per cost category by treatment group

Total costs and costs per cost category by treatment group Data are shown as the mean costs per patient with 95% confidence interval given between brackets and were analyzed with a regression analysis after bootstrapping FU, follow-up Mean total costs and costs per cost category by treatment group The costs for the primary intervention were €551 (95% CI 510–591) in the early mobilization group versus €856 (95% CI 551–1161) in the plaster immobilization group (p = 0.058). Due to the identical, protocolled follow-up, there was no difference in the follow-up costs; €382 (95% CI 349–415) in the early mobilization group versus €399 (95% CI 364–434) in the plaster group (p = 0.481). Details concerning adverse events are shown in Table 5. Adverse events occurred in five patients in the early mobilization group versus seven patients in the plaster immobilization group. Costs for diagnosis and treatment of adverse events were €166 (95% CI − 147 to 478) in the early mobilization group versus €263 (95% CI − 153 to 678) in the plaster immobilization group (p = 0.712). The main determinant in the costs for adverse events were costs for surgery. This applied to three patients, one in the early mobilization group (€4744) versus two in the plaster immobilization group (€3007 and €1687).
Table 5

Adverse events and secondary interventions by treatment group

EarlymobilizationN = 48PlasterimmobilizationN = 52p value
Adverse events5 (10%)7 (13%)0.640
Secondary interventions (N patients)1 (2%)2 (4%)1.000
Secondary interventions (N interventions)1 (2%)2 (4%)1.000
 Arthrolysis10
 Ulnar nerve release01
 Arthroscopy of the wrist01

Data are presented as N (%) and were analyzed using a Chi-squared test

Adverse events and secondary interventions by treatment group Data are presented as N (%) and were analyzed using a Chi-squared test The out of hospital costs during follow-up and rehabilitation were €806 (95% CI 465–1147) in the early mobilization group versus €966 (95% CI 660–1271) in the plaster group (p = 0.483). These costs were mainly due to physical therapy (€738 versus €808; p = 0.693; data not shown). This can be explained by the fact that most patients in both groups attended physical therapy to some degree.

Productivity loss

Work absenteeism did not differ significantly between both groups, although the early mobilization group reported slightly less absenteeism (69% versus 78%; p = 0.572; Table 6). Patients who were treated with early mobilization resumed work 8 days sooner than did patients that were treated with plaster immobilization (10 versus 18 days; p = 0.027). The associated mean costs for lost productivity in the total study population were €1719 (95% CI 465–2974) in the early mobilization group versus €4589 (95% CI 1258–7920) in the plaster group. Despite the large difference of €2870 in favor of early mobilization, this did not reach statistical significance (p = 0.120). When considering only patients that reported sick, the mean costs for productivity loss per absentee were €3751 (95% CI 1174–6329) in the early mobilization group and €9546 (95% CI 2955–16,137) in the plaster group (p = 0.115).
Table 6

Work participation and resumption by treatment group

Early mobilizationN = 48Plaster immobilizationN = 52p value
Work absenteeism (N patients)A22 (69%)25 (78%)0.572a
Resumption at 12 months (N patients)A
 No0 (0%)1 (4%)0.637a
 Partial1 (4%)1 (4%)
 Fully21 (96%)23 (92%)
Time of full resumption (days)B10 (5–16)18 (8–41)0.027b
Hours resumed at 12 months (% of baseline)B100 (100–100)100 (100–100)0.376b

Data are presented as AN (%) or as Bmedian (P25–P75) and were analyzed using a aChi-squared test and bMann–Whitney U test, respectively

Work participation and resumption by treatment group Data are presented as AN (%) or as Bmedian (P25–P75) and were analyzed using a aChi-squared test and bMann–Whitney U test, respectively

Discussion

The FuncSiE trial already showed that patients following a simple elbow dislocation demonstrate earlier recovery of elbow function when treated with early mobilization compared with plaster immobilization. As a consequence, early mobilized patients were able to resume work 8 days earlier. Current data demonstrated that health-related quality of life at 1 year was similar in both groups. Early mobilization showed a consistent trend towards being a less expensive treatment than plaster immobilization for all cost categories studied, yet the difference did not reach statistical significance. Surprisingly, there was also no statistically significant difference in costs for physical therapy between the two groups, despite earlier recovery of elbow function in patients that were treated with early mobilization. This could be explained by the fact that both groups received physical therapy according to an identical treatment protocol. Therefore, these data do not allow to reliably answer the questions whether earlier functional recovery after early mobilization consequently leads to less physical therapy in terms of frequency and duration and whether in that way a reduction in care costs might be realized.

Comparison with other studies

The only recent study on this subject is a retrospective study, which reported the direct healthcare costs of simple elbow dislocations [20]. They divided all patients into three groups according to duration of plaster immobilization (I: < 2 weeks, n = 26, II: 2–3 weeks; n = 27 and III: > 3 weeks; n = 14). They concluded that the length of elbow immobilization did not influence the medical costs. The median direct costs for a simple elbow dislocation in their population were €1375, whereas this was €1904 and €2483 (early mobilization and plaster, respectively) in our study population. Their retrospective study design could explain this difference, as certain cost categories are almost impossible to collect from hospital charts only, which inevitably introduced bias. Another explanation for higher direct costs in our study could be that patients in our study had a protocolled follow-up period of 1 year. This implied that patients visited the out-patient clinic even when the elbow was considered as completely recovered, leading to costs that would otherwise not have been made. No studies report the indirect costs due to productivity loss as a result of simple elbow dislocations.

Strengths and limitations

The most important drawback of this study concerns the absence of significance in the substantial differences between costs in both groups. This was mainly caused by the fact that only three patients underwent surgery as a result of adverse events. This led to excessive total costs for these patients compared with patients who healed uneventfully. These outliers caused considerable variation in costs which could falsely have led to the conclusion that the study lacked power. Moreover, the sample size calculation of the trial was performed from a clinical perspective rather than for cost calculation purposes. Statistically significant difference in total costs could have been demonstrated provided each treatment group should have encompassed 134 patients (β = 0.8, α = 0.05 and two-sided testing). A larger sample size would possibly have captured additional complications, altering direct and indirect costs associated with the care of simple elbow dislocations. Unfortunately, these data did not allow to calculate the cost-effectiveness and cost–utility ratio of early mobilization, as there was no statistically significant difference in health-related quality of life at 1-year follow-up between both groups. On the other hand, there is no relevance in performing a cost-effectiveness or cost–utility analysis for a treatment that leads to earlier functional recovery at almost half the costs per patient (€3449 less expensive). A strength of this study is the data completeness. All data were prospectively collected during the entire rehabilitation process, thus giving a truthful reflection of the actual total costs following a simple elbow dislocation. The incidence rate of elbow dislocations in the Netherlands is 5.6 (per 100,000 person years) [2]. The difference of €3449 in total costs was not statistically significant, but changing treatment protocols for simple elbow dislocations could, in the current Dutch population (16.8 million persons, source: https://www.cbs.nl/nl-NL/menu/cijfers/default.htm, last update April 2014), reduce the care costs by at least 3.2 million euro per year, supporting the societal relevance of early mobilization.

Conclusion

The results of this study show that early mobilization of adult patients with a simple elbow dislocation leads to earlier resumption of activities of daily living and work, which might reduce costs by approximately 50%. The results of the FuncSiE trial provided clinical evidence supporting early mobilization after simple elbow dislocations. Current analysis proved that early mobilization should also be the treatment of choice for this injury from a socio-economic point of view.
  18 in total

1.  [Pure posterior luxation of the elbow in adults: immobilization or early mobilization. A randomized prospective study of 50 cases].

Authors:  M Rafai; A Largab; D Cohen; M Trafeh
Journal:  Chir Main       Date:  1999

2.  The friction cost method for measuring indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten; B M van Ineveld; L van Roijen
Journal:  J Health Econ       Date:  1995-06       Impact factor: 3.883

Review 3.  Guidelines for the conduction of follow-up studies measuring injury-related disability.

Authors:  Ed F Van Beeck; Claus F Larsen; Ronan A Lyons; Willem-Jan Meerding; Saakje Mulder; Marie-Louise Essink-Bot
Journal:  J Trauma       Date:  2007-02

4.  Simple elbow dislocation among adults: a comparative study of two different methods of treatment.

Authors:  Subramanyam Naidu Maripuri; Ujjwal Kanti Debnath; Prabhakar Rao; Khitish Mohanty
Journal:  Injury       Date:  2007-07-20       Impact factor: 2.586

5.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

6.  Simple dislocation of the elbow in the adult. Results after closed treatment.

Authors:  T L Mehlhoff; P C Noble; J B Bennett; H S Tullos
Journal:  J Bone Joint Surg Am       Date:  1988-02       Impact factor: 5.284

7.  Quality of life after multiple trauma--summary and recommendations of the consensus conference.

Authors:  E Neugebauer; B Bouillon; M Bullinger; S Wood-Dauphinée
Journal:  Restor Neurol Neurosci       Date:  2002       Impact factor: 2.406

8.  Functional treatment versus plaster for simple elbow dislocations (FuncSiE): a randomized trial.

Authors:  Jeroen de Haan; Dennis den Hartog; Wim E Tuinebreijer; Gijs I T Iordens; Roelf S Breederveld; Maarten W G A Bronkhorst; Milko M M Bruijninckx; Mark R De Vries; Boudewijn J Dwars; Denise Eygendaal; Robert Haverlag; Sven A G Meylaerts; Jan-Willem R Mulder; Kees J Ponsen; W Herbert Roerdink; Gert R Roukema; Inger B Schipper; Michel A Schouten; Jan Bernard Sintenie; Senail Sivro; Johan G H Van den Brand; Hub G W M Van der Meulen; Tom P H Van Thiel; Arie B Van Vugt; Egbert J M M Verleisdonk; Jos P A M Vroemen; Marco Waleboer; W Jaap Willems; Suzanne Polinder; Peter Patka; Esther M M van Lieshout; Niels W L Schep
Journal:  BMC Musculoskelet Disord       Date:  2010-11-12       Impact factor: 2.362

Review 9.  Simple elbow dislocations: a systematic review of the literature.

Authors:  J de Haan; N W L Schep; W E Tuinebreijer; P Patka; D den Hartog
Journal:  Arch Orthop Trauma Surg       Date:  2009-04-02       Impact factor: 3.067

10.  Trends in incidence and costs of injuries to the shoulder, arm and wrist in The Netherlands between 1986 and 2008.

Authors:  Suzanne Polinder; Gijs I T Iordens; Martien J M Panneman; Denise Eygendaal; Peter Patka; Dennis Den Hartog; Esther M M Van Lieshout
Journal:  BMC Public Health       Date:  2013-06-01       Impact factor: 3.295

View more
  1 in total

1.  Patient satisfaction, joint stability and return to sports following simple elbow dislocations: surgical versus non-surgical treatment.

Authors:  Stephanie Geyer; Lucca Lacheta; Jesse Seilern Und Aspang; Lukas Willinger; Patricia M Lutz; Sebastian Lappen; Andreas B Imhoff; Sebastian Siebenlist
Journal:  Arch Orthop Trauma Surg       Date:  2022-02-26       Impact factor: 3.067

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.